StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Rein Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$18.83M. For fiscal 2025 it was -$19.36M. The highest annual figure on record is -$11.71M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.36M–
FY2024Dec 31, 2024-$22.29M–
FY2023Dec 31, 2023-$19.81M–
FY2022Dec 31, 2022-$24.87M–
FY2021Dec 31, 2021-$23.75M–
FY2020Dec 31, 2020-$20.48M–
FY2019Dec 31, 2019-$26.47M–
FY2018Dec 31, 2018-$27.93M–
FY2017Dec 31, 2017-$20.53M–
FY2016Dec 31, 2016-$15.01M–
FY2015Dec 31, 2015-$11.71M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.64M–
Q1 FY2026Mar 31, 2026-$3.42M–
Q4 FY2025Dec 31, 2025-$3.22M–
Q3 FY2025Sep 30, 2025-$3.55M–
Q2 FY2025Jun 30, 2025-$6.42M–
Q1 FY2025Mar 31, 2025-$6.18M–
Q4 FY2024Dec 31, 2024-$4.81M–
Q3 FY2024Sep 30, 2024-$3.82M–
Q2 FY2024Jun 30, 2024-$8.39M–
Q1 FY2024Mar 31, 2024-$5.27M–
Q4 FY2023Dec 31, 2023-$10.39M–
Q3 FY2023Sep 30, 2023-$1.64M–
Q2 FY2023Jun 30, 2023-$3.12M–
Q1 FY2023Mar 31, 2023-$4.66M–
Q4 FY2022Dec 31, 2022-$4.41M–
Q3 FY2022Sep 30, 2022-$6.97M–
Q2 FY2022Jun 30, 2022-$5.69M–
Q1 FY2022Mar 31, 2022-$7.80M–
Q4 FY2021Dec 31, 2021-$6.26M–
Q3 FY2021Sep 30, 2021-$7.26M–
Q2 FY2021Jun 30, 2021-$3.76M–
Q1 FY2021Mar 31, 2021-$6.48M–
Q4 FY2020Dec 31, 2020-$4.69M–
Q3 FY2020Sep 30, 2020-$5.04M–
Q2 FY2020Jun 30, 2020-$5.07M–
Q1 FY2020Mar 31, 2020-$5.67M–
Q4 FY2019Dec 31, 2019-$6.31M–
Q3 FY2019Sep 30, 2019-$6.98M–
Q2 FY2019Jun 30, 2019-$5.69M–
Q1 FY2019Mar 31, 2019-$7.50M–
Q4 FY2018Dec 31, 2018-$6.66M–
Q3 FY2018Sep 30, 2018-$6.88M–
Q2 FY2018Jun 30, 2018-$7.46M–
Q1 FY2018Mar 31, 2018-$6.93M–
Q4 FY2017Dec 31, 2017-$5.84M–
Q3 FY2017Sep 30, 2017-$5.24M–
Q2 FY2017Jun 30, 2017-$3.51M–
Q1 FY2017Mar 31, 2017-$5.95M–
Q4 FY2016Dec 31, 2016-$4.23M–
Q3 FY2016Sep 30, 2016-$3.93M–

More Rein Therapeutics figures

See a number that looks wrong?